Capturing complex tumour biology in vitro: Histological and molecular characterisation of precision cut slices

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Davies, Emma J ^a   Dong, Meng ^b   Gutekunst, Matthias ^b   Närhi, Katja ^c   Van Zoggel, Hanneke J A A ^d   Blom, Sami ^c   Nagaraj, Ashwini ^c   Metsalu, Tauno ^e   Oswald, Eva ^f   Erkens Schulze, Sigrun ^d   Delgado San Martin, Juan A ^a   Turkki, Riku ^c   Wedge, Stephen R ^a   Af Hällström, Taija M ^c   Schueler, Julia ^f   Van Weerden, Wytske M ^d   Verschuren, Emmy W ^c   Barry, Simon T ^a   Van Der Kuip, Heiko ^b   Hickman, John A ^g  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HELSINKI   (Finland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TARTU   (Estonia)

^f CHARLES RIVER LABORATORIES   (United States)

^g INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; OXYGEN;

ANIMAL; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PHYSIOLOGICAL STRESS; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUE; TISSUE MICROARRAY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BIOMARKERS; CELL LINE, TUMOR; GENE EXPRESSION; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS; OXYGEN; PRINCIPAL COMPONENT ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TISSUE ARRAY ANALYSIS; TISSUE CULTURE TECHNIQUES;

EID: 84949562538     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17187     Document Type: Article

References (32)

1. Bissell, M. J. & Radisky, D. Putting tumours in context. Nat Rev Cancer 1, 46-54, doi: 10.1038/35094059 (2001).
2. Egeblad, M., Nakasone, E. S. & Werb, Z. Tumours as Organs: Complex Tissues that Interface with the Entire Organism. Dev Cell 18, 884-901, doi: http://dx.doi.org/10.1016/j.devcel.2010.05.012 (2010).
3. McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12, 217-228, doi: nrd387010.1038/nrd3870 (2013).
4. Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354, doi: nature1262610.1038/nature12626 (2013).
5. Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res 74, 2377-2384, doi: 0008-5472. CAN-13-297110.1158/0008-5472.CAN-13-2971 (2014).
6. Hickman, J. A. et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumour complexity in vitro/ex vivo. Biotechnol J 9, 1115-1128, doi: 10.1002/biot.201300492 (2014).
7. Shamir, E. R. & Ewald, A. J. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 15, 647-664, doi: nrm387310.1038/nrm3873 (2014).
8. Lancaster, M. A. & Knoblich, J. A. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 345, 1247125, doi: 345/6194/1247125.10.1126/science.1247125 (2014).
9. Majumder, B. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Commun 6, 6169-6183 (2015).
10. van der Kuip, H. et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumour environment. BMC Cancer 6, 86, doi: 1471-2407-6-8610.1186/1471-2407-6-86 (2006).
11. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumours. Proc Natl Acad Sci USA 107, 8352-8356, doi: 0907676107 [pii]10.1073/pnas.0907676107 (2010).
12. Holliday, D. L. et al. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol 66, 253-255, doi: jclinpath-2012-20114710.1136/jclinpath-2012-201147 (2013).
13. Merz, F. et al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol 15, 670-681, doi: not00310.1093/neuonc/not003 (2013).
14. Levenson, A. S. & Jordan, V. C. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57, 3071-3078 (1997).
15. Cho, J., Kim, D., Lee, S. & Lee, Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 19, 1191-1199, doi: me.2004-016210.1210/me.2004-0162 (2005).
16. Hammond, E. et al. The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic. Clin Oncol (R Coll Radiol) 26, 277-288 (2014).
17. Ivanovic, Z. Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol. 219, 271-275 (2009).
18. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat Rev Cancer 6, 583-592 (2006).
19. Farren, M. et al. Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies. Angiogenesis 15, 555-568, doi: 10.1007/s10456-012-9280-2 (2012).
20. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
21. Maddalo, D. et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423-427, doi: 10.1038/nature13902 http://www.nature.com/nature/journal/v516/n7531/abs/nature13902.html#supplementaryinformation (2014).
22. Sanchez-Rivera, F. J. et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428-431, doi: 10.1038/nature13906 http://www.nature.com/nature/journal/v516/n7531/abs/nature13906.html#supplementaryinformation (2014).
23. Van Weerden, W. et al. Development of seven new human prostate tumour xenograft models and their histopathological characterization. Am J Pathol 149, 1055 (1996).
24. Van Weerden, W. et al. Effects of adrenal androgens on the transplantable human prostate tumour PC-82. Endocrinology 131, 2909-2913 (1992).
25. Jackson, E. L. et al. Analysis of lung tumour initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15, 3243-3248 (2001).
26. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007).
27. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protoc 4, 1064-1072 (2009).
28. Marques, R. B. et al. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer 117, 221-229 (2005).
29. Maund, S. L., Nolley, R. & Peehl, D. M. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. Lab Invest 94, 208-221, doi: labinvest201314110.1038/labinvest.2013.141 (2014).
30. Kiviharju-af Hallstrom, T. M. et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 104, 7211-7216, doi: 060929910410.1073/pnas.0609299104 (2007).
31. Smyth, G. K. In Bioinformatics and computational biology solutions using R and Bioconductor 397-420 (Springer, 2005).
32. Jolliffe, I. Principal component analysis. (Wiley Online Library, 2005).